氨苄西林钠舒巴坦钠(Ampicillin Sodium/Sulbactam Sodium) - 药物靶点：PBPs x β-lactamase_在研适应症：肺炎球菌性肺炎，膀胱炎，肺脓肿_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Ampicillin Sodium and Sulbactam Sodium、Ampicillin/Sulbactam、Sulbactam sodium/Ampicillin Sodium

+ [27]

靶点

PBPs x β-lactamase

作用方式

抑制剂

作用机制

PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、β-lactamase抑制剂(β-内酰胺酶抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Meiji Seika Pharma Co., Ltd.

Chemix, Inc.

+ [5]

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1986-12-31),

骨和关节感染中枢神经系统感染妇科感染+ [6]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C24H30N4Na2O9S2

InChIKeyMWBFWOYZSJLWIO-UBWQYZJSSA-N

CAS号117060-71-6

关联

30

项与氨苄西林钠舒巴坦钠相关的临床试验

NCT06440304

/ Recruiting临床4期IIT

Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections: Study Protocol

CRAB infections in ICUs are on the rise, leading to higher morbidity, mortality, and healthcare costs due to resistance to most antibiotics, including carbapenems. The main resistance mechanisms include carbapenemases, efflux pumps, and changes in the bacterial cell wall.
Current treatments include polymyxins (Colistin, Polymyxin B), which are effective but can lead to resistance, aminoglycosides (Amikacin, Gentamicin), which are limited by resistance, and tetracyclines (Tigecycline, Eravacycline), which are effective against CRAB. Fosfomycin is effective in combination treatments, and combination therapy (e.g., colistin with sulbactam, fosfomycin, or eravacycline) can enhance outcomes.
Previous research shows promise for combination therapies, improving treatment efficacy and reducing mortality. New regimens are being studied to find optimal combinations. Individualized dosing is crucial, considering patient-specific factors like age, weight, and renal function. Adjustments depend on the infection site and comorbidities.
Strict infection control and antimicrobial stewardship programs (ASPs) are essential. ASPs focus on optimizing antibiotic use and reducing resistance through education and surveillance. Future directions include continued research for new drugs or combinations and strategies to overcome resistance and improve treatment efficacy.
Study goals include achieving negative samples after 10 days of therapy, 30-day survival, discharge rates, reduced SOFA scores, and improved clinical and radiological findings. A randomized study will compare colistin combined with fosfomycin, ampicillin/sulbactam, and eravacycline.
In summary, treating CRAB infections is complex, requiring combination therapy, individualized dosing, and strict infection control measures.

开始日期2025-01-30

申办/合作机构-

NCT06735703

/ Not yet recruitingN/AIIT

Incidince of PROM with GBS Infection and Prophylaxis Against It

To investigate incidince of prom with GBS infection and role of prophylaxis against it

开始日期2024-12-25

申办/合作机构

Assiut University

NCT05922124

/ Recruiting临床4期IIT

Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)

Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated with colistin alone or colistin combined with meropenem.

开始日期2024-09-01

申办/合作机构

Rambam Health Care Campus

[+2]

100 项与氨苄西林钠舒巴坦钠相关的临床结果

登录后查看更多信息

100 项与氨苄西林钠舒巴坦钠相关的转化医学

登录后查看更多信息

100 项与氨苄西林钠舒巴坦钠相关的专利（医药）

登录后查看更多信息

398

项与氨苄西林钠舒巴坦钠相关的文献（医药）

2025-12-01·JOURNAL DE MYCOLOGIE MEDICALE

Pediatric pneumonia involving Penicillium rolfsii isolated from sputum culture following a plunge pool near-drowning incident

Article

作者: Takahashi, Yoshinori ; Kubo, Tatsuya ; Otani, Hiroki ; Kanamori, Hajime ; Azuma, Tomoko ; Kitaya, Shiori ; Zaimoku, Yoshitaka ; Wada, Taizo ; Watanabe, Akira ; Ikehata, Yui ; Oshima, Megumi ; Yaguchi, Takashi ; Nakade, Junya ; Taniguchi, Takumi ; Matsuda, Yusuke ; Yamazaki, Hiroka ; Miyashita, Daichi ; Tanaka, Yasunari ; Otani, Hatsumi

Penicillium is a ubiquitous fungus found in the soil, decaying plant material, freshwater, and other habitats. Although Penicillium species are generally harmless to humans, they can act as opportunistic pathogens in patients with a compromised immune system. Penicillium rolfsii is primarily known as an endophytic fungus with antioxidant and antibacterial properties, which has not been previously reported in culture tests from invasive human infections. This study reports the case of an eight-year-old boy who developed pneumonia following a near-drowning incident in a river, with P. rolfsii detected in sputum culture. The patient underwent cardiopulmonary resuscitation at the scene and was subsequently transferred to the intensive care unit at our hospital. Chest computed tomography confirmed severe aspiration pneumonia, and empirical treatment with ampicillin-sulbactam was initiated. Based on elevated β-D-glucan levels, voriconazole was added. Sputum cultures revealed the presence of Penicillium species, which were identified as P. rolfsii based on the β-tubulin gene sequence analysis. The treatment was successful, and the patient recovered. An environmental investigation of the plunge pool where the near-drowning incident occurred detected Penicillium species in the water samples. This is the first reported case of P. rolfsii being detected in culture tests of a human invasive infection, particularly in an otherwise healthy child. This case highlights the need for healthcare professionals to consider environmental fungi in Japanese river water as potential causes of invasive infections, such as pneumonia, particularly after near-drowning incidents.

2025-12-01·Journal of Infection and Public Health

Antimicrobial resistance pattern of enterococcus species among clinical isolates in Iran: A systematic review and meta-analysis

Review

作者: Akhgarzad, Ali ; Ahmadian, Maryam ; Nikoohemmat, Mohammad ; Jabbari, Farzaneh ; Alavi Darazam, Ilad ; Ebrahimi, Navid ; Javandoust Gharehbagh, Farid

Enterococcus faecalis (E. faecalis) and Enterococcus faecium (E. faecium) are leading pathogens responsible for both community-acquired and nosocomial infections, with escalating antibiotic resistance reported worldwide. This meta-analysis evaluated resistance patterns in Iran by reviewing 46 studies published between 2017 and 2023, retrieved from PubMed, Scopus, and national Iranian databases (SID, Magiran, Scimed). Among 2379 E. faecalis and 1219 E. faecium isolates, resistance was markedly higher in E. faecium. The highest resistance rate in E. faecalis was observed against trimethoprim/sulfamethoxazole (82.0 %), whereas E. faecium demonstrated the highest resistance to ampicillin-sulbactam (91.7 %). Vancomycin-resistant Enterococci (VRE) prevalence was notably elevated (E. faecium: 52.3 %; E. faecalis: 15.8 %). Linezolid remained the most effective agent, with low resistance rates reported for E. faecalis (1.6 %) and E. faecium (3.1 %). These findings highlight a critical level of antimicrobial resistance in clinical Enterococcus isolates in Iran, underscoring the urgent need for strengthened infection control measures and comprehensive antibiotic stewardship policies.

2025-12-01·VETERINARY JOURNAL

Population pharmacokinetics of intravenous ampicillin in awake and anesthetised dogs

Article

作者: Kohlhauer, Matthias ; Pressiat, Claire ; Hulin, Anne ; Marotto, Stéphanie ; Verwaerde, Patrick ; Maurey, Christelle ; Audrac, Claire

The aim of this study is to describe a population pharmacokinetic model for intravenous ampicillin-sulbactam in awake and anaesthetized dogs in these two treatment scenarios and to compute PK/PD cut-offs (PK/PD_CO). This was a prospective clinical trial in 20 client-owned dogs, either treated by ampicillin after post-surgical infection, or in the context of surgical antimicrobial prophylaxis. All animals received 20 mg/kg of ampicillin by slow iv route. During anesthesia ampicillin administration was repeated every 90 min according to standard recommendations, whereas in awake animals, ampicillin administration was every 8 h. A bi-compartmental model best described the data. Anesthesia and creatinine plasma concentration at the administration correlated with ampicillin clearance, which was 318 ± 36 ml/kg/h in awake animals and 186 ± 12 ml/kg/h in anesthetized animals. Monte-Carlo simulation showed that 20 mg/kg every 8 h in awake dogs led to PK/PD_CO of 0.5 mg/L using a target of 40 %fT>MIC and 0.25 mg/L with 50 % fT>MIC. Administration of ampicillin by prolonged infusion (4 h) every 8 h allowed to achieve a PK/PD_CO of 4 mg/L and 2 mg/L with the 40 % and 50 % targets, respectively. In anesthetized animals, repetition of the 20 mg/kg of ampicillin every 90 min allowed to remain above 4 mg/L during 100 % of the time. Plasma clearance of ampicillin inversely correlates with creatinine plasma concentration in client-owned dogs and is reduced of about 40 % during anesthesia. In awake dogs, the standard regimen of 20 mg/kg every 8 h by intravenous route is probably insufficient to treat soft tissues infections caused by gram-negative bacteria. Using prolonged infusion could help to increase ampicillin efficacy against specific pathogens.

73

项与氨苄西林钠舒巴坦钠相关的新闻（医药）

2025-11-19

·商业新知

科伦药业布局11+9个大品种，拿下百亿粉液双室袋市场！

11月18日，据CDE官网显示，湖南科伦制药递交的3类仿制化药注射用青霉素钠/氯化钠注射液的上市申请获受理，该品种是科伦今年布局的第10款粉液双室袋。截至目前，科伦已有11款粉液双室袋获批，其中7款为国内首仿。截图来源：CDE官网粉液双室袋制剂自20世纪末就已在美国、日本等发达国家的医疗机构中普及应用，并成为输液产品升级的重要方向。科伦作为国内在该领域的领军企业，正积极深耕这一赛道，全力开拓发展。科伦布局10款粉液双室袋，直击百亿蓝海市场据行业报告预估，到2029年，全球粉液双室袋市场规模将达到161.58亿元。在粉液双室袋所涉及的众多药品领域中，注射用青霉素钠/氯化钠注射液在院内市场的发展潜力可期。注射用青霉素钠它以青霉素钠为主成分，可有效治疗敏感菌引发的脓肿、菌血症、肺炎、心内膜炎等多种感染。据摩熵医药数据库显示，注射用青霉素钠在2024年全终端医院销售额超7亿，2025年上半年已超2亿。截图来源：摩熵医药全终端医院销售数据库今年以来，科伦在粉液双室袋领域持续深耕。科伦布局了注射用青霉素钠/氯化钠注射液、注射用头孢噻肟钠/氯化钠注射液、注射用氨苄西林钠/氯化钠注射液、注射用氨苄西林钠舒巴坦钠/氯化钠注射液等10款粉液双室袋，均在审评审批中。其中有9款品种在国内暂无药企获批，科伦若顺利获批，有望拿下这9款首仿，也将进一步巩固其在粉液双室袋的领先地位。科伦今年报产在审的粉液双室袋品种（标红品种为国内暂无仿制药获批上市）数据来源：摩熵医药中国药品审评数据库科伦11款粉液双室袋获批，拿下7款国内首仿科伦药业作为国内粉液双室袋市场龙头，目前已有11款该领域类的产品获批，其中注射用比阿培南/氯化钠注射液、注射用亚胺培南西司他丁钠/氯化钠注射液等7款品种为国内首家。科伦药业已获批的粉液双室袋产品数据来源：摩熵医药中国药品批文数据库科伦药业自2012年转型，已从单一大输液业务成功迈向全面综合发展。目前，科伦药业（含子公司）产品线成果丰硕，在多个领域均取得了显著成绩。在首仿领域，科伦获批数量在国内持续领先。摩熵医药数据库显示，从2022年至2024年科伦拿下了17款首仿。60款品种首家过评，今年2款新药获批上市截至目前，科伦药业（含子公司）在药品过评方面成绩斐然。累计有60款品种首家过评。从剂型分布来看，注射剂表现突出，占比超过69%，主要集中在消化系统及代谢药、全身用抗感染药物等关键治疗领域，为临床治疗提供了更多优质选择。截图来源：摩熵医药过评药品数据库今年以来，科伦药业在首仿领域持续发力，有罗替戈汀贴片、恩扎卢胺片、注射用亚胺培南西司他丁钠/氯化钠注射液、注射用比阿培南/氯化钠注射液、芦曲泊帕片、妥匹坦帕洛诺司琼胶囊这6款首仿获批。截图来源：摩熵医药过评药品数据库新药领域科伦药业成绩亮眼，今年累计获批2款生物药新药，注射用博度曲妥珠单抗为1类新药，西妥昔单抗注射液为3.3类生物类似药，有力充实了公司产品矩阵。小结科伦药业在粉液双室袋领域持续保持深耕，凭借强大的研发实力与前瞻性的战略布局，多款粉液双室袋有望拿下国内首仿，进一步巩固其粉液双室袋领域的领先地位。今年以来，公司在新药研发与仿制药开发方面成果丰硕。截至目前，已有6款首仿药物以及2款新药成功获批上市。若注射用青霉素钠/氯化钠注射液顺利获批，将为其产品矩阵再添强将。

上市批准引进/卖出一致性评价

2025-11-19

·雪球

科伦药业最新动向：百亿双室袋强势上市，9款注射剂首仿完善粉液双室袋布局！

11月18日，据CDE官网显示，湖南$科伦药业(SZ002422)$科伦制药递交的3类仿制化药注射用青霉素钠/氯化钠注射液的上市申请获受理，该品种是科伦今年布局的第10款粉液双室袋。截至目前，科伦已有11款粉液双室袋获批，其中7款为国内首仿。截图来源：CDE官网粉液双室袋制剂自20世纪末就已在美国、日本等发达国家的医疗机构中普及应用，并成为输液产品升级的重要方向。科伦作为国内在该领域的领军企业，正积极深耕这一赛道，全力开拓发展。科伦布局10款粉液双室袋，直击百亿蓝海市场据行业报告预估，到2029年，全球粉液双室袋市场规模将达到161.58亿元。在粉液双室袋所涉及的众多药品领域中，注射用青霉素钠/氯化钠注射液在院内市场的发展潜力可期。注射用青霉素钠它以青霉素钠为主成分，可有效治疗敏感菌引发的脓肿、菌血症、肺炎、心内膜炎等多种感染。据摩熵医药数据库显示，注射用青霉素钠在2024年全终端医院销售额超7亿，2025年上半年已超2亿。截图来源：摩熵医药全终端医院销售数据库今年以来，科伦在粉液双室袋领域持续深耕。科伦布局了注射用青霉素钠/氯化钠注射液、注射用头孢噻肟钠/氯化钠注射液、注射用氨苄西林钠/氯化钠注射液、注射用氨苄西林钠舒巴坦钠/氯化钠注射液等10款粉液双室袋，均在审评审批中。其中有9款品种在国内暂无药企获批，科伦若顺利获批，有望拿下这9款首仿，也将进一步巩固其在粉液双室袋的领先地位。科伦今年报产在审的粉液双室袋品种（标红品种为国内暂无仿制药获批上市）数据来源：摩熵医药中国药品审评数据库科伦11款粉液双室袋获批，拿下7款国内首仿科伦药业作为国内粉液双室袋市场龙头，目前已有11款该领域类的产品获批，其中注射用比阿培南/氯化钠注射液、注射用亚胺培南西司他丁钠/氯化钠注射液等7款品种为国内首家。科伦药业已获批的粉液双室袋产品数据来源：摩熵医药中国药品批文数据库科伦药业自2012年转型，已从单一大输液业务成功迈向全面综合发展。目前，科伦药业（含子公司）产品线成果丰硕，在多个领域均取得了显著成绩。在首仿领域，科伦获批数量在国内持续领先。摩熵医药数据库显示，从2022年至2024年科伦拿下了17款首仿。60款品种首家过评，今年2款新药获批上市截至目前，科伦药业（含子公司）在药品过评方面成绩斐然。累计有60款品种首家过评。从剂型分布来看，注射剂表现突出，占比超过69%，主要集中在消化系统及代谢药、全身用抗感染药物等关键治疗领域，为临床治疗提供了更多优质选择。截图来源：摩熵医药过评药品数据库今年以来，科伦药业在首仿领域持续发力，有罗替戈汀贴片、恩扎卢胺片、注射用亚胺培南西司他丁钠/氯化钠注射液、注射用比阿培南/氯化钠注射液、芦曲泊帕片、妥匹坦帕洛诺司琼胶囊这6款首仿获批。截图来源：摩熵医药过评药品数据库新药领域科伦药业成绩亮眼，今年累计获批2款生物药新药，注射用博度曲妥珠单抗为1类新药，西妥昔单抗注射液为3.3类生物类似药，有力充实了公司产品矩阵。小结科伦药业在粉液双室袋领域持续保持深耕，凭借强大的研发实力与前瞻性的战略布局，多款粉液双室袋有望拿下国内首仿，进一步巩固其粉液双室袋领域的领先地位。今年以来，公司在新药研发与仿制药开发方面成果丰硕。截至目前，已有6款首仿药物以及2款新药成功获批上市。若注射用青霉素钠/氯化钠注射液顺利获批，将为其产品矩阵再添强将。

2025-11-19

·百度百家

国产药王之争升级！科伦亮出底牌：11+9个大品种，强势切入百亿粉液双室袋赛道！

11月18日，据CDE官网显示，湖南科伦制药递交的3类仿制化药注射用青霉素钠/氯化钠注射液的上市申请获受理，该品种是科伦今年布局的第10款粉液双室袋。截至目前，科伦已有11款粉液双室袋获批，其中7款为国内首仿。粉液双室袋制剂自20世纪末就已在美国、日本等发达国家的医疗机构中普及应用，并成为输液产品升级的重要方向。科伦作为国内在该领域的领军企业，正积极深耕这一赛道，全力开拓发展。科伦布局10款粉液双室袋，直击百亿蓝海市场据行业报告预估，到2029年，全球粉液双室袋市场规模将达到161.58亿元。在粉液双室袋所涉及的众多药品领域中，注射用青霉素钠/氯化钠注射液在院内市场的发展潜力可期。注射用青霉素钠它以青霉素钠为主成分，可有效治疗敏感菌引发的脓肿、菌血症、肺炎、心内膜炎等多种感染。据摩熵医药数据库显示，注射用青霉素钠在2024年全终端医院销售额超7亿，2025年上半年已超2亿。今年以来，科伦在粉液双室袋领域持续深耕。科伦布局了注射用青霉素钠/氯化钠注射液、注射用头孢噻肟钠/氯化钠注射液、注射用氨苄西林钠/氯化钠注射液、注射用氨苄西林钠舒巴坦钠/氯化钠注射液等10款粉液双室袋，均在审评审批中。其中有9款品种在国内暂无药企获批，科伦若顺利获批，有望拿下这9款首仿，也将进一步巩固其在粉液双室袋的领先地位。科伦今年报产在审的粉液双室袋品种（标红品种为国内暂无仿制药获批上市）科伦11款粉液双室袋获批，拿下7款国内首仿科伦药业作为国内粉液双室袋市场龙头，目前已有11款该领域类的产品获批，其中注射用比阿培南/氯化钠注射液、注射用亚胺培南西司他丁钠/氯化钠注射液等7款品种为国内首家。科伦药业已获批的粉液双室袋产品科伦药业自2012年转型，已从单一大输液业务成功迈向全面综合发展。目前，科伦药业（含子公司）产品线成果丰硕，在多个领域均取得了显著成绩。在首仿领域，科伦获批数量在国内持续领先。摩熵医药数据库显示，从2022年至2024年科伦拿下了17款首仿。 60款品种首家过评，今年2款新药获批上市截至目前，科伦药业（含子公司）在药品过评方面成绩斐然。累计有60款品种首家过评。从剂型分布来看，注射剂表现突出，占比超过69%，主要集中在消化系统及代谢药、全身用抗感染药物等关键治疗领域，为临床治疗提供了更多优质选择。今年以来，科伦药业在首仿领域持续发力，有罗替戈汀贴片、恩扎卢胺片、注射用亚胺培南西司他丁钠/氯化钠注射液、注射用比阿培南/氯化钠注射液、芦曲泊帕片、妥匹坦帕洛诺司琼胶囊这6款首仿获批。新药领域科伦药业成绩亮眼，今年累计获批2款生物药新药，注射用博度曲妥珠单抗为1类新药，西妥昔单抗注射液为3.3类生物类似药，有力充实了公司产品矩阵。小结科伦药业在粉液双室袋领域持续保持深耕，凭借强大的研发实力与前瞻性的战略布局，多款粉液双室袋有望拿下国内首仿，进一步巩固其粉液双室袋领域的领先地位。今年以来，公司在新药研发与仿制药开发方面成果丰硕。截至目前，已有6款首仿药物以及2款新药成功获批上市。若注射用青霉素钠/氯化钠注射液顺利获批，将为其产品矩阵再添强将。

上市批准引进/卖出一致性评价

100 项与氨苄西林钠舒巴坦钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J01CR01	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肺炎球菌性肺炎	日本	Meiji Seika Pharma Co., Ltd.	2017-01-25
膀胱炎	日本	Pfizer Japan, Inc.	1994-07-01
肺脓肿	日本	Pfizer Japan, Inc.	1994-07-01
腹膜炎	日本	Pfizer Japan, Inc.	1994-07-01
肺炎	日本	Pfizer Japan, Inc.	1994-07-01
细菌感染	中国	中山市力恩普制药有限公司	1993-01-01
骨和关节感染	美国	Pfizer Inc.	1986-12-31
中枢神经系统感染	美国	Pfizer Inc.	1986-12-31
妇科感染	美国	Pfizer Inc.	1986-12-31
腹腔感染	美国	Pfizer Inc.	1986-12-31
下呼吸道感染	美国	Pfizer Inc.	1986-12-31
呼吸道感染	美国	Pfizer Inc.	1986-12-31
脓毒症	美国	Pfizer Inc.	1986-12-31
皮肤和皮肤结构感染	美国	Pfizer Inc.	1986-12-31
泌尿道感染	美国	Pfizer Inc.	1986-12-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
社区获得性肺炎	临床3期	日本	Pfizer Inc.	2010-10-01
细菌性肺炎	临床3期	日本	Pfizer Inc.	2010-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00760006 (CTgov)	临床2期	腭裂	224	Unasyn (Unasyn Antibiotic Arm)	醖壓蓋繭製餘獵範鹽製 = 襯醖憲鏇夢構廠糧鑰壓衊衊齋衊蓋憲選鬱鹹齋 (艱製繭艱構艱網選膚窪, 醖壓觸膚網繭夢鑰齋艱 ~ 觸簾膚窪鏇鏇齋蓋衊鹹) 更多	-	2018-02-01
				saline solution (Saline Placebo Arm)	醖壓蓋繭製餘獵範鹽製 = 壓憲憲鹽膚衊艱鹹築觸衊衊齋衊蓋憲選鬱鹹齋 (艱製繭艱構艱網選膚窪, 憲醖憲糧獵憲鬱衊鹹選 ~ 選簾遞獵製選鹽鏇製顧) 更多
NCT00879190 (CTgov)	临床2/3期	绒毛膜羊膜炎	92	Unasyn (Unasyn (Ampicillin/Sulbactam))	鹽構憲範鏇淵鏇憲窪憲 = 衊餘簾願範壓遞艱淵襯窪遞顧顧顧鏇網獵廠鏇 (鑰膚憲網鬱積範願鹹糧, 夢觸壓顧積遞廠醖醖製 ~ 夢網糧壓醖範製鹽顧獵) 更多	-	2017-03-15
				gentamicin+Ampicillin (Ampicillin/Gentamicin)	鹽構憲範鏇淵鏇憲窪憲 = 鑰網鏇糧遞淵積網範蓋窪遞顧顧顧鏇網獵廠鏇 (鑰膚憲網鬱積範願鹹糧, 齋膚醖觸醖製網餘廠繭 ~ 獵壓窪製選齋襯壓積繭) 更多
NCT01189487 (Pubmed \| J Infect Chemother)	临床3期	社区获得性肺炎	47	Sulbactam/Ampicillin 3 g QID	製鹹鹽積遞鏇糧構廠遞(獵壓蓋艱觸網鹹鹽淵艱) = 顧膚膚構網顧繭壓築齋廠顧餘襯繭鬱鑰選淵鹹 (糧簾鏇構蓋簾艱衊廠壓 ) 更多	积极	2015-03-01
NCT00630513 (T.E.A. Study, Pubmed \| BMC Gastroenterol)	临床4期	腹腔感染	142	Ertapenem	顧鬱顧鑰積艱艱構構鏇(憲淵糧鹹醖鏇鹹築網築) = 顧鑰膚襯觸鹹襯遞淵鏇範範壓襯積糧醖鹽構膚 (範選繭廠襯淵積糧獵網 )	积极	2013-04-30
NCT00356148 (Pubmed \| Ann Surg)	临床4期	乳腺癌	369	prophylactic antibiotic administration (Prophylaxis group)	夢壓壓糧鑰鏇醖廠憲簾(構蓋齋齋餘構窪繭選顧) = 襯餘遞淵衊鹽鬱窪鏇糧鹽構簾顧積網襯積鑰醖 (膚網襯選繭窪鬱鏇蓋夢 ) 更多	积极	2013-01-01
				prophylactic antibiotic administration (Control group)	夢壓壓糧鑰鏇醖廠憲簾(構蓋齋齋餘構窪繭選顧) = 遞繭鬱簾憲範憲餘築簾鹽構簾顧積網襯積鑰醖 (膚網襯選繭窪鬱鏇蓋夢 ) 更多
NCT00368537 (CTgov)	临床4期	细菌性皮肤疾病	550	Tigecycline (Tigecycline)	遞壓製鬱襯遞選獵夢獵 = 齋鏇鬱鏇壓膚網積壓簾鑰鏇廠憲廠淵糧範憲憲 (遞鏇簾餘衊窪遞遞夢糧, 選膚餘繭築構淵憲鹽選 ~ 積築範製鑰醖膚鏇窪夢) 更多	-	2012-08-09
				Ampicillin-Sulbactam+Amoxicillin-Clavulanate (Ampicillin-Sulbactam or Amoxicillin-Clavulanate)	遞壓製鬱襯遞選獵夢獵 = 簾獵網範簾遞獵構齋簾鑰鏇廠憲廠淵糧範憲憲 (遞鏇簾餘衊窪遞遞夢糧, 獵製衊選鑰鏇鏇遞顧鹽 ~ 網鏇廠範襯襯鹽獵鑰膚) 更多
NCT01189487 (CTgov)	临床3期	细菌性肺炎 \| 社区获得性肺炎	47	ampicillin sodium/sulbactam sodium	糧鹽艱餘鹽夢衊齋蓋糧 = 憲衊網構遞選鹽餘衊齋壓遞繭製壓齋顧夢糧窪 (膚鏇積醖顧襯夢襯淵鏇, 鹹築膚壓繭鹽積簾選鏇 ~ 憲鹹壓鏇淵憲糧觸糧範) 更多	-	2012-05-18
NCT01138852 (Pubmed \| BMC Infect Dis)	临床4期	-	176	Ampicillin-sulbactam	製顧遞艱衊網壓積淵壓(淵鬱膚膚鏇醖範壓觸壓) = 網網齋艱積鏇鏇衊選艱積蓋網顧憲觸蓋窪簾遞 (遞構遞簾壓獵憲選蓋蓋 )	-	2010-11-30
				Cefuroxime	製顧遞艱衊網壓積淵壓(淵鬱膚膚鏇醖範壓觸壓) = 鹹憲衊繭淵醖鬱糧構範積蓋網顧憲觸蓋窪簾遞 (遞構遞簾壓獵憲選蓋蓋 )